发布会现场。人民网记者丁亦鑫 摄 人民网北京10月27日电 （记者丁亦鑫）秋冬季节，呼吸道传染病多发。面对市面上多种呼吸道传染病疫苗，该如何选择？不同人群有哪些接种建议？ 安徽省疾病预防控制中心主任医师吴家兵在27日国家卫生健康委召开的新闻发布会上作出解答。 "疫苗是预防呼吸道传染病最经济、最有效的措施。我们公众应该结合个人的健康状况和接种禁忌，及时接种相关的疫苗。"吴家兵表示，当前，可以预 防呼吸道传染病的疫苗种类很多，包括流感疫苗、水痘疫苗、肺炎球菌疫苗。应当根据不同人群的健康状况、年龄特点以及暴露的风险，科学选择接种，做 到"分类施策，愿种尽种"。 对于儿童和青少年，免疫系统尚未发育完全，是呼吸道疾病的高发人群。适龄对象除了要完成国家免疫规划疫苗，比如麻腮风疫苗，含百日咳成份疫 苗、流脑疫苗这些疫苗的接种以外，建议6月龄以上的儿童和青少年每年都要接种流感疫苗，还建议儿童按照免疫程序完成肺炎球菌疫苗、b型流感嗜血杆菌 疫苗、水痘疫苗等疫苗的接种。 对于成年人来说，特别是医务人员、教师、公共服务行业从业者以及一些有基础疾病的人，建议每年都要接种流感疫苗，并且根据健康状况接种肺炎球 菌疫苗。 对于一些慢性病患 ...

会上，有记者提问，目前市面上有多种呼吸道传染病的疫苗，比如流感、肺炎球菌疫苗。对于民众 来说，如何来科学选择？针对于不同年龄段的人群，有哪些接种建议？ 对于成年人来说，特别是医务人员、教师、公共服务行业从业者以及一些有基础疾病的人，建议每 年都要接种流感疫苗，并且根据健康状况接种肺炎球菌疫苗。一些慢性病患者，比如糖尿病、慢阻肺、 心血管疾病患者，感染呼吸道疾病病原体后容易发生重症，更要优先接种。 对于老年人群，由于免疫力下降，且大部分伴有基础性疾病，易感染流感和肺炎等呼吸道疾病，是 感染后造成重症和死亡的高危群体，建议每年接种流感疫苗，同时也推荐接种肺炎球菌疫苗，以降低肺 炎以及住院的风险。 吴家兵表示，总体来看，疫苗是预防呼吸道传染病最经济、最有效的措施。公众应该结合个人的健 康状况和接种禁忌，及时接种相关的疫苗。 安徽省疾病预防控制中心主任医师吴家兵表示，当前，可以预防呼吸道传染病的疫苗种类很多，包 括流感疫苗、水痘疫苗、肺炎球菌疫苗。应当根据不同人群的健康状况、年龄特点以及暴露的风险，科 学选择接种，做到"分类施策，愿种尽种"。具体来说： 对于儿童和青少年，免疫系统尚未发育完全，是呼吸道疾病的高发人群。 ...

对于成年人，特别是医务人员、教师、公共服务行业从业者以及一些有基础疾病的人，建议每年都要接 种流感疫苗，并且根据健康状况接种肺炎球菌疫苗。一些慢性病患者，比如糖尿病、慢阻肺、心血管疾 病患者，感染呼吸道疾病病原体后容易发生重症，更要优先接种。 对于老年人群，由于免疫力下降，且大部分伴有基础性疾病，易感染流感和肺炎等呼吸道疾病，是感染 后造成重症和死亡的高危群体，建议每年接种流感疫苗，同时也推荐接种肺炎球菌疫苗，以降低肺炎以 及住院的风险。 中新健康｜如何科学选择呼吸道传染病疫苗？专家解答 中新网10月27日电 国家卫生健康委27日召开新闻发布会，介绍时令节气与健康(霜降)有关情况，并答记 者问。会上，安徽省疾病预防控制中心主任医师吴家兵称，当前，可以预防呼吸道传染病的疫苗种类很 多，包括流感疫苗、水痘疫苗、肺炎球菌疫苗。应当根据不同人群的健康状况、年龄特点以及暴露的风 险，科学选择接种，做到"分类施策，愿种尽种"。 吴家兵表示，对于儿童和青少年，免疫系统尚未发育完全，是呼吸道疾病的高发人群。适龄对象除了要 完成国家免疫规划疫苗，比如麻腮风疫苗，含百日咳成份疫苗、流脑疫苗这些疫苗的接种以外，建议6 月龄以上的儿 ...

对于成年人，特别是医务人员、教师、公共服务行业从业者及有基础疾病者，建议每年接种流感疫苗， 并根据健康状况接种肺炎球菌疫苗。慢性病患者如糖尿病、慢阻肺、心血管疾病患者感染呼吸道疾病病 原体后易发生重症，应优先接种。 对于老年人群，由于免疫力下降，且大部分伴有基础性疾病，易感染流感和肺炎等呼吸道疾病，是感染 后造成重症和死亡的高危群体。建议每年接种流感疫苗，同时也推荐接种肺炎球菌疫苗，降低肺炎及住 院风险。总体来看，疫苗是预防呼吸道传染病最经济、最有效的措施。公众应结合个人健康状况和接种 禁忌，及时接种相关疫苗。 （文章来源：央视新闻） 国家卫生健康委今天举行新闻发布会，介绍时令节气与健康有关情况。安徽省疾病预防控制中心主任医 师吴家兵介绍，当前，可以预防呼吸道传染病的疫苗种类较多，包括流感疫苗、水痘疫苗、肺炎球菌疫 苗等。应当根据不同人群的健康状况、年龄特点和暴露风险，科学选择接种，做到"分类施策，愿种尽 种"。 对于儿童和青少年，免疫系统尚未发育完全，是呼吸道感染的高发人群。适龄对象除了完成国家免疫规 划疫苗如麻腮风疫苗、含百日咳成分疫苗、流脑疫苗等疫苗的接种以外，建议6月龄以上儿童和青少年 每年接种流感疫 ...

封面新闻记者 赵奕 国庆中秋假期刚刚结束，成都已从"假期模式"无缝切换至"攻坚状态"，在"一季关两年"的关键节点拉响了"开局即冲刺"的奋进号角。 从消费热力持续升温，双节期间旅游总花费293.5亿元、机场吞吐量纪录刷新，到重大项目火力全开，以复星医药创新疫苗总部为代表的一批标志性项目 取得关键进展，再到"成都造·全球销"出海行动开拓国际市场，彰显"成都造"的全球竞争力。消费"热力"与项目"火力"双向奔赴，点燃了成都冲刺年度目 标，助推高质量发展的双核引擎。 "双节"期间游客在都江堰景区观赏熊猫（图据人民日报） "双节"吸金293.5亿开好局 超六百场活动"花式"促消费 这个"双节"假期，成都用一组组扎实的数据，展现了其作为国际消费中心城市和旅游目的地的强劲"吸金力"与"吸引力"。据文旅大数据综合测算，全市8 天共接待游客2862.3万人次，实现旅游总花费293.5亿元。更为亮眼的是，人均消费达到1025.3元，同比增长7.7%，充分展现了消费品质的提升与内需潜力 的有效释放。 文旅市场的热度，也在交通枢纽得到直观体现。成都国际航空枢纽在假期中格外繁忙，共保障航班起降1.4万架次，完成旅客吞吐量227.6万人次 ...

Core Viewpoint - Zhifei Biological, once thriving on the agency of Merck's HPV vaccine, is now facing multiple challenges including high inventory, difficult receivables, and transformation issues, resulting in its worst interim performance since its listing in 2010 [2][3]. Financial Performance - In the first half of 2025, Zhifei Biological reported revenue of 4.919 billion yuan, a year-on-year decline of 73.06%. The net profit attributable to shareholders was a loss of 599 million yuan, a year-on-year decrease of 126.72%, marking the first half-year loss since the company's listing [3][5]. - The company has been in a continuous loss state for four consecutive quarters [5]. Business Model Challenges - The "agency + self-developed" business model has revealed several risks amid industry fluctuations. The agency business is heavily reliant on upstream suppliers, and any changes in their strategies can directly impact performance. Additionally, the long development cycle and high investment in self-developed products pose risks of product shortages if new products are not timely launched [7]. - Balancing agency introduction and self-development is crucial for domestic vaccine companies. While agency business can quickly enrich the product line, it is essential to choose products with market potential and technological advantages [7]. Dependency on HPV Vaccine - Zhifei Biological's business is highly dependent on the agency of Merck's HPV vaccine, which contributed approximately 68% of revenue in 2024. The company faces two core challenges: increasing channel conflicts as international manufacturers collaborate directly with local firms, and relatively low contribution from self-developed products, which accounts for less than 20% of revenue [8]. Decline in Product Sales - In the first half of 2025, the batch issuance volume of core agency products significantly declined, particularly the four-valent HPV vaccine, which dropped from 466,000 units in the first half of 2024 to 0 units, a decrease of 100%. The nine-valent HPV vaccine issuance fell from 18.272 million units to 4.239 million units, a decline of 76.8% [10][11]. - The revenue from agency products halved, decreasing from 51.89 billion yuan in 2023 to 24.67 billion yuan in 2024, and further down to 4.37 billion yuan in the first half of 2025, a year-on-year decrease of 75.2% [12]. Self-Developed Products - Self-developed product revenue in the first half of 2025 was 500 million yuan, accounting for 10.15% of total revenue, with a gross margin of 78.50%, although this was an 8.06 percentage point decline year-on-year [14]. - The batch issuance volume of self-developed products like ACYW135 and Hib vaccines saw significant declines, with Hib vaccine issuance down 66.46% year-on-year [15][16]. R&D Investment - The company has historically maintained a low R&D expense ratio, below 4%, compared to peers. Although the R&D expense ratio reached 8.5% in the first half of 2025, this was primarily due to a significant drop in revenue [17]. - The projected annual R&D investment for 2025 is approximately 1.27 billion yuan, which is less than the previous year's 1.391 billion yuan [17].

Group 1 - The stock price of CanSino on August 26 was 84.82 yuan, down 3.37 yuan or 3.82% from the previous trading day [1] - The opening price was 87.70 yuan, with a high of 87.99 yuan and a low of 84.60 yuan, and the trading volume was 33,388 hands with a transaction amount of 287 million yuan [1] Group 2 - CanSino is a biopharmaceutical company focused on vaccine research, production, and commercialization, with main products including meningococcal vaccines and COVID-19 vaccines [1] - The company belongs to the bioproducts sector [1] Group 3 - According to the latest semi-annual report, CanSino achieved operating revenue of 382 million yuan in the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to the parent company was a loss of 13.49 million yuan, significantly narrowing the loss by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - During the reporting period, sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, a year-on-year increase of 38.43% [1] Group 4 - On August 26, the net outflow of main funds for CanSino was 71.34 million yuan, accounting for 0.73% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 67.14 million yuan, representing 0.69% of the circulating market value [1]

Summary of Zhifei Biological Conference Call Company Overview - **Company**: Zhifei Biological Products Co., Ltd. - **Industry**: Biopharmaceuticals, specifically focusing on vaccines and metabolic disease treatments Key Points and Arguments Financial Performance - **Revenue Decline**: Starting from Q2 2024, the company experienced a significant decline in performance, particularly in HPV vaccine sales, attributed to economic cycles, reduced consumer willingness, and vaccine hesitancy [2][3][4] - **Losses**: The company reported three consecutive quarters of losses as of Q1 2025, with accounts receivable dropping from 30 billion to 14 billion, but with extended turnover days [3][10] - **Cash Dividends**: In 2024, the company distributed a total cash dividend of 2.394 billion, alongside a stock buyback exceeding 300 million [6][11] Strategic Measures - **Response to Challenges**: The company is actively seeking new growth points and has adjusted procurement plans with partners like GSK and Merck to align with market demand [2][4] - **Inventory Management**: Focus on reducing inventory levels, particularly for HPV and shingles vaccines, which are significant contributors to the current stock levels [8][9] - **Sales Promotion**: Enhanced marketing policies and public awareness campaigns to increase vaccination rates [4][9] Research and Development - **R&D Progress**: The company has 34 self-developed projects, with 19 in clinical trials or registration stages, including advancements in pneumonia, meningitis, and adult vaccines [5][15] - **Expansion into Metabolic Diseases**: Acquisition of a controlling stake in Cheng'an Biological, gaining access to GLP-1 receptor agonists, thus expanding into the metabolic disease sector [5][15] Corporate Governance and Social Responsibility - **Sustainability Report**: The company released its first sustainability report, emphasizing R&D, governance, quality management, and community engagement [12][13] - **Charitable Contributions**: Participation in 12 charitable projects with total donations exceeding 400 million, showcasing commitment to social responsibility [7][13] Future Outlook - **Operational Focus for 2025**: Key initiatives include inventory reduction, debt recovery, and risk management, with a strong emphasis on HPV and shingles vaccine sales [8][9] - **Market Expansion**: Plans to enhance international market presence and expedite the registration of new vaccine products [9][10] Market Challenges - **Industry Downturn**: The company is navigating a challenging environment characterized by high investment requirements and long product cycles, necessitating a focus on maintaining operational stability [11][15] Conclusion - **Long-term Vision**: Zhifei Biological aims to solidify its position as a leading biopharmaceutical company through innovation, strategic partnerships, and a commitment to sustainable practices, while addressing immediate operational challenges [6][15]